Trop­i­cal dis­ease PRV fix didn’t stop No­var­tis from win­ning an­oth­er

7 years ago
Pharma

FDA doc re­veals agency charged Im­munomedics with da­ta in­tegri­ty breach af­ter Au­gust plant in­spec­tion

7 years ago
Pharma

J&J R&D vet Pe­ter Tum­mi­no joins the Big Phar­ma ex­o­dus, leap­ing to Nim­bus as CSO; Ca­dent taps Jodie Mor­ri­son for CEO

7 years ago
Peer Review

GW Phar­ma cannabi­noid to be test­ed for Alzheimer's ag­i­ta­tion; Acor­da rev­enue plum­mets as gener­ics evis­cer­ate its ...

7 years ago
News Briefing

Morn­ing­side spawned Stealth Bio’s IPO stum­bles out of the gate, rais­ing $78M

7 years ago
Financing

Bay­er, Ori­on prostate can­cer drug cuts risk of metas­ta­sis or death by more than 50% in key study

7 years ago
R&D

James Wil­son turns to old men­tor for gene ther­a­py star­tup's star-stud­ded $115M launch round

7 years ago
Financing
Startups

The top 10 pipeline blowups, set­backs and sna­fus for H2 2018

7 years ago
R&D
Special

In­di­a's gener­ic drug mak­er Glen­mark draws up a US-based brand­ed drugs unit

7 years ago
R&D

Ap­pro­pri­a­tions bill would give FDA $269M boost over FY2018 bud­get

7 years ago
Pharma

Mer­ck goes in deep­er with Keytru­da/Lyn­parza com­bo; PureTech un­veils stem cell ther­a­py start­up

7 years ago
News Briefing

An­tipsy­chot­ic from Lund­beck, Ot­su­ka flops again in PhI­II tri­als — this time in bipo­lar pa­tients

7 years ago
R&D

Mo­tif Bio's turn­around quest for once-re­ject­ed an­tibi­ot­ic hits the CRL wall

7 years ago
R&D

Ra­maswamy's Ax­o­vant whips up a CNS spin­off with a $530M deal and a syn­di­cate of sup­port­ers

7 years ago
Startups
Pharma

David de Graaf has a new gig, a new idea and a new start­up — hunt­ing some new mon­ey

7 years ago
People
Startups

As­traZeneca drops an OX40 can­cer drug can­di­date in Q4 pipeline cleanup

7 years ago
R&D

DBV es­ti­mates peanut al­ler­gy drug sub­mis­sion in Q3, but it may be too lit­tle too late in race with Aim­mune

7 years ago
Pharma

In HKEX's first test in 2019, CStone seeks up to $304M in IPO for­tune

7 years ago
Financing
China

As­traZeneca sweeps away the Med­Im­mune name as CEO So­ri­ot re­struc­tures R&D

7 years ago
R&D

Do­nat­ed glob­al­ly since 2005, No­var­tis' flat­worm treat­ment Egat­en wins FDA nod — and a PRV

7 years ago
Pharma

Charles Riv­er drops $510M to bag non-clin­i­cal CRO; Mag­pie rais­es $14.8M Se­ries B to mod­ern­ize tra­di­tion­al Chi­nese ...

7 years ago
News Briefing

Vas Narasimhan earned a big pay hike when he moved to the CEO's suite at No­var­tis

7 years ago
People

J&J to aug­ment sur­gi­cal of­fer­ings with $3.4B ac­qui­si­tion of ro­bot­ics firm Au­ris Health

7 years ago
Deals

Busy VC 5AM eclipses $125M tar­get for fund to in­ject cap­i­tal in­to ex­ist­ing port­fo­lio, meets goal for sixth biotech ...

7 years ago
Financing
First page Previous page 959960961962963964965 Next page Last page
A service from the Financial Times